News stories about Aerie Pharmaceuticals (NASDAQ:AERI) have trended positive recently, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Aerie Pharmaceuticals earned a daily sentiment score of 0.48 on Accern’s scale. Accern also assigned news articles about the company an impact score of 0 out of 100, indicating that recent press coverage is extremely unlikely to have an impact on the company’s share price in the next several days.
These are some of the media stories that may have effected Accern Sentiment Analysis’s scoring:
- Aerie Pharmaceuticals (AERI) Earning Somewhat Positive Media Coverage, Study Finds (techdeezer.com)
- Karp Capital Management Corp Acquires New Stake in Aerie Pharmaceuticals, Inc. (AERI) – Newburgh Gazette (newburghgazette.com)
- Stifel Nicolaus Believes Aerie Pharma (NASDAQ: AERI) Still Has Room to Grow – Analyst Ratings (analystratings.com)
- Aerie Pharmaceuticals Inc (AERI) Showing Bullish Money Flow … – Stock Press Daily (stockpressdaily.com)
- What's in the Cards for Aerie (AERI) This Earnings Season? (finance.yahoo.com)
AERI has been the subject of a number of research analyst reports. HC Wainwright restated a “buy” rating and issued a $69.00 target price on shares of Aerie Pharmaceuticals in a report on Thursday, May 25th. BidaskClub lowered Aerie Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, June 17th. Canaccord Genuity restated a “buy” rating and issued a $56.00 target price on shares of Aerie Pharmaceuticals in a report on Tuesday, April 18th. Stifel Nicolaus reiterated a “buy” rating on shares of Aerie Pharmaceuticals in a report on Friday, May 26th. Finally, Aegis reiterated a “buy” rating and set a $63.00 price objective on shares of Aerie Pharmaceuticals in a report on Thursday, April 13th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $66.08.
Shares of Aerie Pharmaceuticals (NASDAQ:AERI) traded up 2.40% during midday trading on Friday, hitting $55.50. The stock had a trading volume of 222,224 shares. Aerie Pharmaceuticals has a 1-year low of $16.61 and a 1-year high of $59.50. The company’s 50 day moving average price is $54.10 and its 200-day moving average price is $47.17. The firm’s market capitalization is $1.87 billion.
Aerie Pharmaceuticals (NASDAQ:AERI) last released its quarterly earnings data on Tuesday, May 2nd. The company reported ($0.76) earnings per share for the quarter, missing the consensus estimate of ($0.74) by $0.02. Equities analysts predict that Aerie Pharmaceuticals will post ($2.56) earnings per share for the current year.
In related news, major shareholder Foresite Capital Fund Ii, L.P. sold 20,000 shares of the company’s stock in a transaction dated Friday, May 26th. The shares were sold at an average price of $55.95, for a total value of $1,119,000.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 9.36% of the stock is currently owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: This news story was first published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be accessed at https://www.chaffeybreeze.com/2017/07/30/aerie-pharmaceuticals-nasdaqaeri-given-daily-media-impact-score-of-0-48-updated-updated-updated.html.
Aerie Pharmaceuticals Company Profile
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).
Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.